Characterization of multidrug resistance and monitoring of tumor response by combined 31P and 1H nuclear magnetic resonance spectroscopic analysis

Anti-Cancer Drugs

Volumn 9, Issue 5, 1998, Pages 449-456

  Venkatesan, Paragiri V ^a   Saravanan, Kannappa ^a   Nagarajan, Bala ^a  

^a CANCER INSTITUTE WIA   (India)

Author keywords

Metabolites; Multidrug resistance; NMR; Tumor response

Indexed keywords

CREATINE PHOSPHATE; DOXORUBICIN; LACTIC ACID; MITOXANTRONE; PHOSPHATE; PHOSPHOLIPID;

ANIMAL CELL; ARTICLE; CELL METABOLISM; CONTROLLED STUDY; GLYCOLYSIS; HUMAN; LEUKEMIA CELL; MOUSE; MULTIDRUG RESISTANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL EXTRACTS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENERGY METABOLISM; EUKARYOTIC CELLS; HYDROGEN; MAGNETIC RESONANCE SPECTROSCOPY; MITOXANTRONE; PERCHLORIC ACID; PHOSPHOCREATINE; PHOSPHOLIPIDS; PHOSPHORUS; TUMOR CELLS, CULTURED;

EID: 0031843774     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199806000-00012     Document Type: Article

References (19)

1. Roepe PD. The role of the MDR protein in altered drug translocation across tumor cell membranes. Riochim Biophys Acta 1995; 1241: 385-405.
2. 31P nuclear magnetic resonance spectroscopy: a review. Cancer Res 1989; 49: 4075-85.
3. Daly PF, Cohen JS. Magnetic resonance spectroscopy of tumors and potential in viva clinical application: a review. Cancer Res 1989, 49: 770-9.
4. Negendank WG, Padavic-Shaller KA, Li C, et al. Metabolic-characterization of human non-Hodgkin's lymphomas in vivo using proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res 1995; 55: 3286-94.
5. Senthilvelan S, Saravanan K, Jagannathan NR, Nagarajan B. Monitoring therapeutic response of tumors by nuclear magnetic resonance spectroscopy. Med Sci Res 1991; 19: 609-11.
6. Venkatesan PV, Nagarajan B. Flow injection analysis quantifies multidrug resistance phenotype. Cancer Lett 1995; 97: 93-8.
7. Venkatesan PV, Nagarajan B. Assessment of cross-resistance in adriamycin- and mitoxantrone-resistant cells by flow injection analysis. J Clin Biochem Nutr 1995; 19: 123-30.
8. De Jong S, Mulder NH, de Vries EGE, Robillard GT. NMR spectroscopy analysis of phosphorus metabolites and the effect of adriamycin on these metabolite levels in an adriamycin-sensitive and -resistant human small cell lung carcinoma cell line. Br J Cancer 1991; 63: 205-12.
9. 31P nuclear magnetic resonance spectroscopy, histology and cytokinetics of a xenografted hypopharynx carcinoma following treatment with cisplatin: comparison in three sublines with increasing resistance. Br J Cancer 1991; 64: 485-93.
10. 31P MRS: possible clinical significance. Mayo Clin Proc 1988; 63: 1199-206.
11. Lyon RC, Cohen JS, Faustino PJ, Megnin F, Myers CE. Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy. Cancer Res 1988; 48: 870-7.
12. 31P NMR spectroscopy. J Biol Chem 1987; 262: 14875-8.
13. 31P nuclear magnetic resonance spectroscopy in murine mammary adenocarcinomas. Cancer Res 1987; 47: 3396-401.
14. 1H NMR spectroscopy of tumors in vivo: untreated growth and response to chemotherapy. Ann NY Acad Sci 1987; 508: 200-15.
15. Reeve RG, Xiong J, Morgan J, Blechen NM. Expression of apoptosis regulatory genes in lung tumor cells lines: relationship to p53 expression and relevance to acquired resistance. Br J Cancer 1996; 73: 1193-200.
16. Linn SC, Honkoop AH, Hoekman K, Van der Valk P, Pinedo HM, Giaccone G. p53 and P-glycoprotein are often coexpressed and are associated with poor prognosis in breast cancer. Br J Cancer 1996; 74: 63-8.
17. 31P magnetic resonance spectroscopy. Cancer Res 1986; 46: 4087-90.
18. 31P NMR studies of cell extracts: differences in metabolism between drug-sensitive and drug-resistant MCF-7 human breast cancer cells. Biochem Biophys Res Commun 1990; 169: 383-90.
19. 31P nuclear magnetic resonance characterization and 2-deoxyglucose toxicity. Cancer Res 1991; 51: 1638-44.